Overall survival benefit of immune checkpoint inhibitor immunotherapy for advanced esophagogastric adenocarcinomas with low/intermediate PD-L1 expression (CPS <10)

Study ID	CPS	Number of patients	Median OS (immunotherapy plus chemotherapy versus chemotherapy alone)	HR for overall survival (95% CI)
CheckMate 649^[1]	<10	795 (includes MSI-H)	12.4 versus 12.5 months	0.91 (0.78-1.06)
KEYNOTE 590^[2]	<10	100 (adenocarcinoma only)	12.7 versus 8.4 months	0.66 (0.42-1.04)
KEYNOTE-062^[3]	1 to 9	318	12.5 versus 11.1 months	0.84 (0.66-1.06)

PD-L1: programmed cell death ligand 1; CPS: combined positive score; OS: overall survival; HR: hazard ratio; CI: confidence interval; MSI-H: high levels of microsatellite instability; NR: not reported.

References:

Shitara K, Ajani JA, Moehler MH, et al. Nivolumab plus chemotherapy or ipilimumab in gastro-esophageal cancer. Nature 2022; 603:942.
Sun J-M, Shen L, Shah MA, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet 2021; 398:759.
Zhao JJ, Yap DWT, Chan YH, et al. Low Programmed Death-Ligand 1-Expressing Subgroup Outcomes of First-Line Immune Checkpoint Inhibitors in Gastric or Esophageal Adenocarcinoma. J Clin Oncol 2022; 40:392.

Graphic 135164 Version 2.0

خرید پکیج

Overall survival benefit of immune checkpoint inhibitor immunotherapy for advanced esophagogastric adenocarcinomas with low/intermediate PD-L1 expression (CPS <10)